GLP-3-R 30MG
$155.00
Retatrutide is a synthetic triple receptor agonist peptide that binds the GLP-1, GIP, and glucagon receptors.
Unlike single-receptor peptides, it engages three distinct G protein-coupled receptors, which allows researchers to study the combined signaling of all three pathways in a single compound rather than across three separate preparations.
Researchers study Retatrutide in:
- GLP-1, GIP, and glucagon receptor binding assays
- cAMP signaling and receptor activation studies
- Comparative studies against single- and dual-agonist peptides
- Peptide stability and formulation research
For research use only. Not for human or veterinary use.
MECHANISM
How Does It Work?
Retatrutide activates three receptors involved in appetite regulation, fat metabolism, and blood sugar control.
| GLP-1 Receptor | GIP Receptor | Glucagon Receptor |
|---|---|---|
| Signals fullness, slows digestion, and helps stabilize blood sugar after meals. | Enhances insulin response and helps regulate how fat is stored and utilized. | Signals the body to use stored fat for energy while helping prevent blood sugar from dropping too low. |
Research suggests these three pathways create a compounding metabolic effect, with each receptor amplifying the activity of the others.
PHYSICAL PROPERTIES
| Property | Details |
|---|---|
| Form | Lyophilized powder |
| Color | White to off-white |
| Molecular Weight | 4,967.5 g/mol |
| Storage | Refrigerated 36–46°F (2–8°C), avoid freeze-thaw cycles |
| Reconstitution | Bacteriostatic or sterile water recommended |
| Stability | 24 months lyophilized, use within 30 days after reconstitution |
POTENTIAL SIDE EFFECTS IN RESEARCH
The following effects have been observed in preclinical and clinical studies. Researchers should monitor subjects carefully and document all observations.
| Nausea & Digestive Discomfort | Increased Heart Rate |
|---|---|
| The most commonly reported observation. Usually mild and tends to decrease as research protocols continue. | Mild increases in resting heart rate have been observed in some subjects. |
| Injection Site Irritation | Low Blood Sugar |
|---|---|
| Minor redness or swelling at the administration site. Typically temporary and resolves without intervention. | Rare, but possible — especially when combined with other glucose-lowering compounds. |
| Reduced Appetite | Changes in Digestion Speed |
|---|---|
| A significant reduction in appetite is consistently observed in research models and is considered an expected effect. | Slower gastric emptying has been observed, meaning food moves more slowly through the digestive system. |
DISCLAIMER
This product is exclusively for laboratory research. Not approved for human or veterinary use.
All products sold by Ikon Peptides are intended exclusively for in-vitro laboratory research. Not approved for human consumption or veterinary use. These statements have not been evaluated by the FDA.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Related products
